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Abstract
Objective
Erythropoietin (EPO) is a clinically available hematopoietic cytokine. EPO has shown bene-
ficial effects in the context of spinal cord injury and other neurological conditions. The aim of
this study was to evaluate the effect of EPO on a rat model of spinal cord compression-
induced cervical myelopathy and to explore the possibility of its use as a pharmacological
treatment.
Methods
To develop the compression-induced cervical myelopathy model, an expandable polymer
was implanted under the C5-C6 laminae of rats. EPO administration was started 8 weeks
after implantation of a polymer. Motor function of rotarod performance and grip strength was
measured after surgery, and motor neurons were evaluated with H-E, NeuN and choline
acetyltransferase staining. Apoptotic cell death was assessed with TUNEL and Caspase-3
staining. The 5HT, GAP-43 and synaptophysin were evaluated to investigate the protection
and plasticity of axons. Amyloid beta precursor protein (APP) was assessed to evaluate
axonal injury.
To assess transfer of EPO into spinal cord tissue, the EPO levels in spinal cord tissue
were measured with an ELISA for each group after subcutaneous injection of EPO.
Results
High-dose EPO maintained motor function in the compression groups. EPO significantly
prevented the loss of motor neurons and significantly decreased neuronal apoptotic cells.
Expression of 5HT and synaptophysin was significantly preserved in the EPO group. APP
expression was partly reduced in the EPO group. The EPO levels in spinal cord tissue were
significantly higher in the high-dose EPO group than other groups.
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Conclusion
EPO improved motor function in rats with compression-induced cervical myelopathy. EPO
suppressed neuronal cell apoptosis, protected motor neurons, and induced axonal protec-
tion and plasticity. The neuroprotective effects were produced following transfer of EPO into
the spinal cord tissue. These findings suggest that EPO has high potential as a treatment for
degenerative cervical myelopathy.
Introduction
As the population ages, degenerative changes in the cervical spine progress. The spinal canal
gradually narrows due to cervical spondylosis, disc hernia, and ossification of the posterior
longitudinal ligament [1] [2]. This chronic compression of the cervical spinal cord causes
degenerative cervical myelopathy. The symptoms of degenerative cervical myelopathy such as
motor weakness, sensory disturbances, decreased fine motor coordination, and spastic gait
gradually progress over time. Mechanical stress as a consequence of focal compression, which
induces spinal cord ischemia at the compressed segment, is an important component in the
pathogenesis of degenerative cervical myelopathy [3]. At this time, surgical decompression is
often performed to treat degenerative cervical myelopathy [4] [5] [6]. At present, however,
there is no accredited medical treatment which improve the neurological status in patients
with worsening degenerative cervical myelopathy.
To elucidate the biological mechanism of degenerative cervical myelopathy and develop a
treatment strategy for it, a co-author, Kim, established a novel experimental model of spinal
cord compression-induced cervical myelopathy [7]. This model is created by inserting a sheet
of water-absorbing urethane-compound polymer under the laminae of rats. This model
induces delayed motor dysfunction and reproduces the characteristic course of clinical delayed
degenerative cervical myelopathy. Using this model, we have previously demonstrated that
pharmacological agents, such as Limaprost alfadex, prostaglandin E1 derivative, and Cilostazol,
a selective type III phosphodiesterase inhibitor, ameliorate compression-induced cervical mye-
lopathy [8] [9]. However, functional recovery from developing compression myelopathy has
not been elucidated in those studies.
We recently confirmed that granulocyte colony-stimulating factor (G-CSF) improves
motor function in the progressive phase of compression myelopathy and preserves anterior
horn motor neurons in the rat spinal cord compression-induced cervical myelopathy model
[10]. However, in healthy people, G-CSF causes marked leukocytosis, which commonly results
in fever, arthralgia, and rarely, thromboembolism and splenomegaly [11].
Erythropoietin (EPO) is a physiological hematopoietic cytokine similar to G-CSF. EPO is a
30.4-kDa glycoprotein secreted from the kidney that stimulates red blood cell (RBC) produc-
tion (erythropoiesis) after binding to the EPO receptor in the bone marrow [12]. EPO is com-
monly used in anemic patients undergoing chronic hemodialysis or suffering from cancer and
undergoing chemotherapy [13] [14]. EPO is also used for preoperative autologous blood dona-
tion in hematologically healthy individuals [15]. Therefore, EPO can often be used safely, even
in elderly patients or those with critical disease.
In addition, EPO has multifunctional tissue-protective effects, including anti-apoptotic,
anti-inflammatory, anti-oxidative, and angiogenic effects [16] [17] [18]. During the last two
decades, a number of studies have described its neuroprotective effects in cerebral infarction,
brain contusion, and acute spinal cord injury (SCI) in laboratory investigations [19] [20] [21]
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[22] [23]. Those papers reported beneficial effects of EPO on neuroprotection, angiogenesis,
and anti-apoptosis in the brain and spinal cord [18] [24]. Recently, recombinant human EPO
(rhEPO) was preliminarily used in a randomized clinical trial of acute SCI, and results indi-
cated the possibility of treating acute SCI with EPO [25].
However, no reports have shown the neuroprotective effect of EPO for spinal cord com-
pression-induced cervical myelopathy in experimental or clinical studies.
Here, we investigated the neuroprotective effects of EPO for degenerative cervical myelopa-
thy using our established rat model of spinal cord compression [7].
Materials and methods
Animal maintenance
This study was approved by the Institutional Animal Care and Use Committee of Yokohama
City University School of Medicine (IRB: F-A-15-022). Male Wistar rats (12 weeks old, weight
250–300 g; Japan SLC Inc., Hamamatsu, Japan) were housed in cages for 3 weeks before sur-
gery for adaptation to the environment. All rats were trained to exercise on the rotarod device
and to undergo forepaw grip strength measurement for 2 weeks before surgery. Throughout
this experimental period, the rats had free access to water and food. Body weight was recorded
every week during this study.
Surgical procedure to create the spinal cord compression-induced cervical
myelopathy model
The detailed surgical procedure to create the spinal cord compression-induced cervical mye-
lopathy model has been described [7]. Under general anesthesia with 2% isoflurane, a midline
incision was made in the nuchal area, and the C3-Th1 laminae were exposed. A sheet of
expandable urethane compound polymer (size 2 × 6 × 0.7 mm; Aquaprene C1, Sanyo Chemi-
cal Industries, Ltd., Tokyo, Japan) was inserted into the sublaminar space of C5-C6 (Fig 1A
and 1B). This sheet gradually expands to 230% of the original volume over 48–72 hours by
absorbing water in the tissue. In this model, the decline in motor function is delayed, with a
latency period after compression introduction, and then gradual progression, whereas no
acute damage suggestive of SCI is observed. This model reproduces the characteristic course
and features of clinical degenerative cervical myelopathy [7].
Fig 1. The spinal cord compression-induced cervical myelopathy model. A: Computed tomography (CT) axial view at the
C5 levels, 0.5 mm above the intervertebral foramen. B: CT sagittal view of the cervical spine. Aquaprene1 (expandable
urethane compound sheet, size 2 × 6 × 0.7 mm) was inserted under the C5-C6 laminae.
https://doi.org/10.1371/journal.pone.0214351.g001
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Experimental design
Preliminary experiment. In a preliminary experiment, we confirmed the course of motor
function decline in this model to determine when to administer EPO in the treatment
experiment.
Briefly, 40 rats were allocated to two groups; sham operation group (n = 15) and compres-
sion group (n = 25). In the sham group, rats underwent a sham operation; the polymer sheet
was placed under the laminae and removed immediately. In the compression group, this poly-
mer sheet was left in place and continued to compress the spinal cord chronically (Fig 1A and
1B). The motor functions were evaluated once a week from 1 week before surgery to 26 weeks
after surgery.
Treatment experiment (Fig 2). In the treatment experiment, 48 rats were allocated to
four groups; sham group (sham operation + normal saline [NS]; n = 12), vehicle group (com-
pression + NS; n = 12), low-dose EPO group (compression + EPO low dose; n = 12), and high-
dose EPO group (compression + EPO high dose; n = 12). From the results of the preliminary
experiments, the motor function was significantly decreased 8 weeks after surgery. Therefore,
administration of rhEPO or NS was started from 8 weeks after surgery and lasted until 16
weeks; the frequency of administration was twice a week. In the sham group, rats underwent
the sham operation and received administration of NS subcutaneously. In the vehicle group,
rats underwent polymer sheet implantation and received administration of NS subcutane-
ously. In the low-dose EPO group, spinal cord compression-induced cervical myelopathy
model rats received rhEPO 500 IU/kg/day (rhEPO; kindly provided by Chugai Pharmaceutical
Co., Ltd., Tokyo, Japan) subcutaneously. In the high-dose EPO group, spinal cord compres-
sion-induced cervical myelopathy rats received administration of rhEPO 5000 IU/kg/day sub-
cutaneously. The motor functions were also evaluated once a week from 1 week before surgery
to 16 weeks after surgery. Histological assessment of the anterior horn (H-E, Neu N, ChAT)
was evaluated at 16 weeks after surgery (Fig 2A).
All rats were weighed weekly.
Motor function analysis
Rotarod performance. Rotarod performance was assessed by using the rotarod device
(ENV-557, Med Associates Inc., St. Albans, VT, USA). Based on our previous research, a mod-
erate rotation speed of 10 rpm was set [7] [8] [9] [10]. All rats could walk on the rotarod for
more than 300 seconds before surgery. Therefore, 300 seconds was set as the cut-off. Three tri-
als in each session were performed for all rats. We recorded the longest duration time of the
three trials.
Forelimb grip strength. Forelimb grip strength was assessed by using a digital force
meter (MK-380CM/F, Muromachi Kikai, Tokyo, Japan). We assessed grip strength according
to the methods of Meyer et al [26]. The animals were evaluated before surgery and once a week
after surgery. All rats also performed three trials in each session, and the maximum score (in
newtons: N) was used for data analysis.
Histological analysis
Hematoxylin and eosin (H-E) staining at C5-6 levels. At 16 weeks after surgery, trans-
cardial perfusion was performed with 4% paraformaldehyde in phosphate-buffered saline
(PBS) in all rats. The spinal cord segment at C5-6 was removed en bloc and placed in 4% para-
formaldehyde solution for 3 days. After this process, these C5-6 segments were embedded in
paraffin and sectioned at a slice thickness of 5 μm and a gap interval of 5 μm over 1000 μm
length, according to stereological considerations of motor neurons [7] [8] [9] [10]. One
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hundred specimens of all rats were stained with H-E. Motor neurons have large nuclei and
well-developed, densely stained Nissl bodies in the cytoplasm. The characteristic large nucleo-
lus has a uniform diameter of approximately 5 μm [27] [28]. In H-E-stained sections, we
regarded such cells as motor neurons. Motor neurons on both sides of the anterior horn gray
matter were counted.
H-E staining at C2, Th4, Th12 levels. At 16 weeks after surgery, transcardial perfusion
was performed with 4% paraformaldehyde in phosphate-buffered saline (PBS) in another 9
Fig 2. Treatment experiment: Experimental design. Administration of low-dose and high-dose EPO and normal saline was started twice a week at 8
weeks postoperatively. A: Forty-eight rats were divided into four groups (sham, vehicle, high-dose EPO, and low-dose EPO). The motor functions of
rotarod performance and grip strength were evaluated once a week before surgery to 16 weeks after surgery. Every rat was sacrificed, and histological
analysis was performed (H-E staining and NeuN staining). B: Another 18 rats were divided into three groups (sham, vehicle, and high-dose EPO).
Treatment was done from 8 weeks to 10 weeks after surgery, and all rats were sacrificed at 10 weeks after surgery. Apoptotic cells were evaluated with
TUNEL staining at 10 weeks after surgery. C: Another 12 rats were divided into three groups (vehicle, high-dose EPO, and low-dose EPO). Each
single treatment was done 8 weeks after surgery. All rats were sacrificed 12 hours after injection, and the EPO levels in the spinal cord was measured
using a rhEPO enzyme-linked immunosorbent assay (ELISA).
https://doi.org/10.1371/journal.pone.0214351.g002
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rats (sham group; n = 3, vehicle group; n = 3, and high-dose EPO group; n = 3). Each segment
was cut into 10 sections in the same manner as described above. Ten specimens of all rats were
stained with H-E. Motor neurons on both sides of the anterior horn gray matter were counted.
NeuN staining. NeuN protein appears in neuron-specific nuclei. The nucleus of the
motor neuron is more clearly detected with NeuN staining compared with H-E staining.
In the treatment experiment, 10 specimens (thickness = 5 μm, gap interval = 50 μm) of five
rats in all groups were stained with immunohistochemistry. Both sides of the anterior horn
were also evaluated with NeuN staining following application of the chromogen diaminoben-
zidine (Dako North America, Santa Clala, CA, USA, 1:100) using the labeled streptavidin bio-
tin technique [29]. Rabbit anti-NeuN (EMD Millipore Corporation, Burlington, MA, USA,
1:100) was used as the primary antibody. NeuN-positive cells on both sides of the anterior
horn gray matter were counted.
Choline Acetyltransferase (ChAT) staining. In spinal cord, ChAT is expressed in motor
neurons and pre-ganglionic autonomic neurons. Here, ChAT staining was used as specifica-
tion of motor neurons.
In the treatment experiment, 3 specimens (thickness = 5 μm, gap interval = 50 μm) of one
rat in vehicle and high-dose EPO groups at 16 weeks after surgery were stained with immuno-
histochemistry. Both sides of the anterior horn were also evaluated with ChAT staining follow-
ing application of the chromogen diaminobenzidine (Dako North America, Santa Clala, CA,
USA, 1:100) using the labeled streptavidin biotin technique [29]. Rabbit anti-ChAT (GeneTex,
Alton Pkwy Irvine, CA, USA, 1:100) was used as the primary antibody. ChAT-positive cells on
both sides of the anterior horn gray matter were counted.
Glial fibrillary acid protein (GFAP) staining. GFAP is an intermediate filament protein
that is specifically expressed in cells of the astroglia lineage and is widely used as an astrocytic
marker in the brain and spinal cord. In the treatment experiment, 3 specimens
(thickness = 5 μm, gap interval = 50 μm) of one rat in vehicle and high-dose EPO groups at 16
weeks after surgery were stained with immunohistochemistry. Both sides of the anterior horn
were also evaluated with GFAP staining following application of the chromogen diaminoben-
zidine (Dako North America, Santa Clala, CA, USA, 1:100) using the labeled streptavidin bio-
tin technique [29]. Rabbit anti-GFAP (NOVUS, Centennial, CO, USA, 1:100) was used as the
primary antibody. GFAP positive astrocytes on both sides of the anterior horn gray matter
were counted.
Allophycocyanin (APC) staining. APC is expressed in the oligodendrocyte in the brain
and spinal cord. Here, APC staining was used as specification of oligodendrocytes.
In the treatment experiment, 3 specimens (thickness = 5 μm, gap interval = 50 μm) of one
rat in Vehicle and high-dose EPO groups at 16 weeks after surgery were stained with immuno-
histochemistry. Both sides of the anterior horn were also evaluated with APC staining follow-
ing application of the chromogen diaminobenzidine (Dako North America, Santa Clala, CA,
USA, 1:100) using the labeled streptavidin biotin technique [29]. Rabbit anti-APC (abcam,
Cambridge, Cambridgeshire, UK, 1:100) was used as the primary antibody. APC positive oli-
godendrocytes on both sides of the anterior horn gray matter were evaluated.
Erythropoietin receptor (EPO-R) staining. In the treatment experiment, 3 specimens
(thickness = 5 μm, gap interval = 50 μm) of one rat in vehicle and high-dose EPO groups at 10
weeks after surgery were stained with immunohistochemistry. Both sides of the anterior horn
were also evaluated with EPO-R staining following application of the chromogen diaminoben-
zidine (Dako North America, Santa Clala, CA, USA, 1:100) using the labeled streptavidin bio-
tin technique [29]. Rabbit anti-EPO-R (NOVUS, Centennial, CO, USA, 1:100) was used as the
primary antibody. EPO-R-positive cells on both sides of the anterior horn gray matter were
counted.
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5-hydroxytryptamine (5-HT) staining. 5-hydroxytryptamine (5-HT) (Serotonin) is a
monoamine neurotransmitter in raphespinal axons. Here, 5-HT staining was used as an axo-
nal marker of raphespinal tract.
In the treatment experiment, 3 specimens (thickness = 5 μm, gap interval = 50 μm) of one
rat in vehicle and high-dose EPO groups at 10 and 16 weeks after surgery were stained with
immunohistochemistry. Both sides of the anterior horn were also evaluated with 5-HT stain-
ing following application of the chromogen diaminobenzidine (Dako North America, Santa
Clala, CA, USA, 1:100) using the labeled streptavidin biotin technique [29]. Rabbit anti-5-HT
(NOVUS, Centennial, CO, USA, 1:100) was used as the primary antibody. 5-HT-positive
axons on both sides of the anterior horn gray matter were evaluated.
Growth Associated Protein 43 (GAP-43) staining. GAP-43 is a membrane bound pro-
tein expressed in extending axons and its expression likely represents a high-growth state [30].
In the treatment experiment, 3 specimens (thickness = 5 μm, gap interval = 50 μm) of one
rat in vehicle and high-dose EPO groups at 10 and 16 weeks after surgery were stained with
immunohistochemistry. Both sides of the anterior horn were also evaluated with GAP-43
staining following application of the chromogen diaminobenzidine (Dako North America,
Santa Clala, CA, USA, 1:100) using the labeled streptavidin biotin technique [29]. Rabbit anti-
GAP-43 (Proteintech Group, Chicago, IL, USA, 1:100) was used as the primary antibody.
GAP-43-positive cells on both sides of the anterior horn gray matter were evaluated.
Synaptophysin staining. Synaptophysin is a synaptic vesicle glycoprotein in neurons in
the brain and spinal cord. Here, synaptophysin was used as an axonal synaptic marker in spi-
nal cord.
In the treatment experiment, 3 specimens (thickness = 5 μm, gap interval = 50 μm) of one
rat in the vehicle and high-dose EPO groups at 10 and 16 weeks after surgery were stained
with immunohistochemistry. Both sides of the anterior horn were also evaluated with synapto-
physin staining following application of the chromogen diaminobenzidine (Dako North
America, Santa Clala, CA, USA, 1:100) using the labeled streptavidin biotin technique [29].
Rabbit anti-Synaptophysin (NOVUS, Centennial, CO, USA, 1:100) was used as the primary
antibody. Synaptophysin positive axons on both sides of the anterior horn white matter were
counted.
Amyloid Precursor Protein (APP) staining. APP is an integral membrane protein
expressed in the synapses of neurons. APP is well known as the precursor molecule whose pro-
teolysis generates beta amyloid. Increased APP in axons is thought to represent protein accu-
mulation due to disruption of axon flow [31].
Here, APP staining was used as a marker of axonal and neuronal damage [32].
In the treatment experiment, 3 specimens (thickness = 5 μm, gap interval = 50 μm) of one
rat in vehicle and high-dose EPO groups at 10 and 16 weeks after surgery were stained with
immunohistochemistry. Both sides of the anterior horn were also evaluated with APP staining
following application of the chromogen diaminobenzidine (Dako North America, Santa Clala,
CA, USA, 1:100) using the labeled streptavidin biotin technique [29]. Rabbit anti-APP (Gene-
Tex, Alton Pkwy Irvine, CA, USA, 1:100) was used as the primary antibody. APP-positive cells
on both sides of the anterior horn gray matter and white matter were counted.
Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin
nick end labeling (TUNEL) staining. Apoptotic cell death was investigated 10 weeks after
surgery. Another 18 rats (Sham group; n = 6, Vehicle group; n = 6, high-dose EPO group;
n = 6) were perfused transcardially with 4% paraformaldehyde in PBS (Fig 2B). The C5-6
segment of the spinal cord was embedded in optimal cutting temperature compound and
frozen in liquid nitrogen. Three sections from C5-6 segments (thickness = 20 μm, gap
interval = 50 μm) were cut in a cryostat and stained with the In Situ Cell Death Detection Kit,
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POD (Roche, Basel, Switzerland) according to the manufacturer’s recommendations. Nuclei
were counterstained with 4’,6-diamidino-2-phenylindole (DAPI, 1:5000 in PBS) (Molecular
Probes, Eugene, OR, USA). The TUNEL stain signal was observed under an FV300 confocal
microscope (Olympus Optical Company, Ltd., Tokyo, Japan). TUNEL- and DAPI-positive
cells were counted, and the ratios of apoptotic cells to total nuclei were evaluated in each
group.
Caspase-3 staining. Caspase-3 staining was evaluated as an indicator of the course of apo-
ptotic cell death.
In the treatment experiment, 3 specimens (thickness = 5 μm, gap interval = 50 μm) of one
rat in the vehicle and high-dose EPO groups at 10 weeks after surgery were stained with immu-
nohistochemistry. Both sides of the anterior horn were also evaluated with Caspase-3 staining
following application of the chromogen diaminobenzidine (Dako North America, Santa Clala,
CA, USA, 1:100) using the labeled streptavidin biotin technique [29]. Rabbit anti-Caspase-3
(NOVUS, Centennial, CO, USA, 1:100) was used as the primary antibody. Caspase-3-positive
cells on both sides of the anterior horn gray matter were evaluated.
Hematological assessment. Another 12 rats were divided into three groups. All these rats
underwent the operation to place the polymer sheet under the C5-6 laminae and were treated
with NS or rhEPO twice a week from 8 weeks after surgery. The vehicle group, low-dose EPO
group, and high-dose EPO group were examined. All rats were subjected to inhalation anes-
thesia with 2% isoflurane. Blood samples (0.5 ml/body) were collected by venipuncture from
the tail vein at 2, 4, and 6 weeks after the first EPO administration. Blood samples were col-
lected into blood collection tubes with EDTA 2K (BD Microtainer, Japan Becton, Dickinson
and Company, Tokyo, Japan) immediately. RBC, hemoglobin (Hb), and hematocrit (Ht) val-
ues were assessed with an automated hematology analyzer (XE 2100, Sysmex, Hyogo, Japan).
Assessing rhEPO levels in spinal cord tissue. To assess whether subcutaneously injected
EPO was transferred to the spinal cord, we measured EPO levels in the spinal cord with an
enzyme-linked immunosorbent assay. Another 12 rats were divided into three groups; vehicle
group, low-dose EPO group, and high-dose EPO group. All these rats underwent the operation
in which the polymer sheet remained under the C5-6 laminae. They received NS or rhEPO 8
weeks after surgery. Twelve hours after subcutaneous injection of NS or rhEPO, all rats were
sacrificed under anesthesia, and blood was completely removed by transcardial perfusion with
PBS to exclude rhEPO from blood (Fig 2C). The spinal cord segment at the C5-6 levels was
removed en bloc. These tissues were homogenized in IP buffer with an ultra Turrax homoge-
nizer and centrifuged at 12000 rpm at 4˚C for 5 min. Supernatants were removed and analyzed
to determine the levels of rhEPO in the spinal cord tissue. The total protein of the spinal cord
tissue was determined using bovine serum albumin as a standard. The rhEPO concentration
in spinal cord tissue was measured with a rhEPO enzyme-linked immunosorbent assay kit
(R&D Systems Europe, Abingdon, UK) according to the manufacturer’s instructions. The con-
centration was described as the rhEPO levels per 1 g tissue (mIU/g) and tissue dose % of
injected dose (%ID).
Statistical analysis
GraphPad Prism 6 software for Windows (GraphPad Software Inc., La Jolla, CA, USA) was
used for statistical analysis. Data are expressed as the mean ± standard error of the mean. The
duration of walking on the rotarod, forelimb grip strength, body weight and hematological
data were analyzed using two-way repeated-measures analysis of variance (ANOVA), which
takes into account the passage of time. The number of anterior horn motor neurons with H-E,
NeuN, and TUNEL staining and the rhEPO levels in spinal cord were tested using one-way
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ANOVA, which does not take into account the passage of time. The number of ChAT, APP,
EPO-R-positive cells and Synaptophysin positive axons were tested using unpaired t-test. P
values<0.05 were regarded as significant.
Results
Motor function
Preliminary experiment. Rotarod performance declined gradually with a latency period
of 4 weeks in the compression group. At 7 weeks after surgery, the walking duration signifi-
cantly decreased in the compression group compared to the sham group (P < 0.001: two-way
ANOVA). In the compression group, the duration declined gradually and reached a plateau
after 16 weeks (Fig 3A).
Forelimb grip strength increased with weight gain in all groups until 5 weeks after surgery.
In the sham group, it reached a plateau after 5 weeks from surgery. On the other hand, it
started to decrease from 6 weeks in the compression group. The strength gradually declined
and significantly decreased after 7 weeks compared with the sham group (P< 0.001: two-way
ANOVA) (Fig 3B).
Based on these results, we decided to administer EPO beginning 8 weeks after surgery as a
treatment experiment.
Treatment experiment. The rotarod performance of the compression groups (vehicle,
low-dose EPO, and high-dose EPO groups) declined gradually from 5 weeks after surgery, and
a significant decrease was seen from 7 weeks compared with the sham group (P< 0.005: two-
way ANOVA) as in the preliminary experiments (Fig 4A).
After EPO administration beginning 8 weeks after surgery, rotarod performance started to
improve in the treatment groups (low-dose and high-dose EPO groups).
Especially in the high-dose EPO group, rotarod performance significantly improved com-
pared with the other compression groups (vehicle and low-dose EPO groups), although the
performance gradually declined from 13 weeks. The effects of EPO continued for 5 weeks after
EPO administration (P< 0.01: two-way ANOVA). Furthermore, the high-dose EPO group
improved to the levels at which no significant difference in motor function was seen between
Fig 3. Preliminary experiment. A: Time course of rotarod performance measured by walking time on a rotarod (cut-off 300 seconds). In the
compression group, the walking time gradually started to decline from 4 weeks and showed a significant decrease at 7 weeks after surgery
(P< 0.001: two-way ANOVA). The performance reached a plateau with a low duration of about 50 seconds after 15 weeks. B: Time course of
forelimb grip strength. In the compression group, grip strength decreased at 1 week after surgery due to surgery, but gradually increased as body
weight increased. However, grip strength gradually declined from 6 weeks, and showed a significant difference at 7 weeks after surgery
(P< 0.0001: two-way ANOVA) After that, the strength continued to decrease gradually, reaching approximately 10.5 N at 26 weeks
postoperatively.
https://doi.org/10.1371/journal.pone.0214351.g003
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the sham and high-dose EPO groups at 9 weeks after surgery (N.S: one-way ANOVA). The
low-dose EPO group showed slightly improved rotarod performance, but did not show signifi-
cant improvement compared with the vehicle group (Fig 4A).
The forelimb grip strength of the compression groups decreased at 1 week after surgery but
started to recover gradually from 2 weeks after surgery. The strength of the compression group
showed an improvement course equal to that of the sham group from 2 weeks after surgery
and then started to decrease gradually from 7 weeks; at this time, the strength was significantly
decreased compared with the sham group (P < 0.001: two-way ANOVA) (Fig 4B).
After EPO administration at 8 weeks after surgery, grip strength started to improve in the
treatment groups (low-dose EPO, high-dose EPO groups).
In the high-dose EPO group, the strength significantly improved compared with the other
compression groups (vehicle and low-dose EPO groups) (P < 0.0001: two-way ANOVA). Its
effects continued throughout the period of EPO administration (9 to 16 weeks after surgery),
although the strength gradually decreased from 4 weeks after EPO administration.
In contrast, the low-dose EPO group showed a slight improvement in strength, but it did
not show significant improvement compared with the vehicle group (Fig 4B).
Histopathological analysis
H-E staining in C5-6 levels. At 16 weeks after surgery, the loss of anterior horn motor
neurons and vacuolar degeneration in the spinal cord were observed in H-E-stained sections
from the compression groups (vehicle, low-dose EPO, and high-dose EPO group) (Fig 5A).
The numbers of motor neurons were 1834.7 ± 115.4 (sham group), 1421.6 ± 50.1 (vehicle
group), 1484.7 ± 74.2 (low-dose EPO group), and 1640.0 ± 66.9 (high-dose EPO group). The
number of motor neurons on both sides of the anterior horn was significantly decreased in
every compression group compared to the non-compression sham group (P < 0.0001: one-
Fig 4. Treatment experiment: Motor function. A: Time course of rotarod performance measured by walking time on a rotarod (cut-off 300 seconds).
In the compression models (vehicle, low-dose EPO, and high-dose EPO groups), rotarod performance gradually declined from 3 weeks after surgery,
and showed a significant difference at 7 weeks after surgery. After administration of EPO from 8 weeks, rotarod performance improved in the EPO
groups. Especially in the high-dose EPO group, performance markedly improved. This effect was maintained with a significant difference by week 13
after surgery (P< 0.01: two-way ANOVA). In the low-dose EPO group, slight improvement in rotarod performance was observed, but it did not reach
statistical significance compared with the vehicle group. B: Time course of forelimb grip strength. In the compression groups, the strength started to
decline from 6 weeks after surgery, and a significant decline was observed at 7 weeks. EPO was administered at 8 weeks, and grip strength improved,
especially in the high-dose EPO group. Significant improvement was seen from 9 weeks in the high-dose EPO group (P< 0.0001: two-way ANOVA)
and continued up to 16 weeks after surgery. In the low-dose EPO group, grip strength slightly improved, but no significant difference was found
compared with the vehicle group.
https://doi.org/10.1371/journal.pone.0214351.g004
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Fig 5. Treatment experiment: Anterior motor neurons. A: Top panels: CT axial view in C5. In the compression groups (vehicle, low-dose EPO, and high-dose
EPO), the spinal cord was compressed by Aquaprene1 (expandable urethane compound sheet, size 2 × 6 × 0.7 mm). The yellow dotted figure shows the outline of
the spinal cord. Second panels: The spinal cord at the C5 levels was sliced into 5-μm thick sections at 16 weeks after surgery. Hematoxylin and eosin staining of cross
sections of spinal cord is shown (original magnification ×4, scale bar = 100 μm). In the compression groups, the spinal cord was flattened. Black box shows the region
of the anterior horn. Third panels: The black box in the second panel was magnified (×10, scale bar 20 μm). Cells with large nuclei and well-developed, densely
stained Nissl bodies in the cytoplasm indicate motor neurons. In the vehicle and low-dose EPO groups, motor neurons decreased, and vacuolar degeneration was
obvious. In the high-dose EPO group, motor neurons were preserved, although vacuolar degeneration was present. Fourth panels: NeuN staining of the anterior horn
(×10, scale bar 20 μm). The nuclei of motor neurons are clearly detected with NeuN staining compared with H-E staining. Motor neurons decreased in the vehicle
and low-dose EPO groups, but they were preserved in the high-dose EPO group. Bottom panels: ChAT staining of the anterior horn (×40, scale bar 20 μm). Motor
neurons were stained with ChAT staining. Motor neurons were preserved in the high-dose EPO groups compared to Vehicle groups. B: Counting of anterior horn
cells in H-E-stained tissue. The number of cells with large nuclei in the anterior horn was counted in every group. The number was significantly decreased in the
compression groups compared with the sham group (�P< 0.0001: one-way ANOVA). However, in the high-dose EPO group, the number was significantly preserved
compared with the other two compression groups (vehicle and low-dose EPO groups). C: Counting of anterior horn cells in NeuN-stained tissue. NeuN-positive cells
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way ANOVA). In the high-dose EPO group, however, the motor neurons were significantly
preserved compared with the other compression groups (vehicle and low-dose EPO groups;
P< 0.0001: one-way ANOVA) (Fig 5B).
Cell counting of NeuN-positive cells. The number of NeuN-positive cells in 10 slices of
each group was 286.8 ± 17.6 (sham group), 176.0 ± 14.3 (Vehicle group), 178.0 ± 17.1 (low-
dose EPO group), and 220.4 ± 9.4 (high-dose EPO group). NeuN-positive cells in each com-
pression group decreased compared with the sham group (P < 0.0001: one-way ANOVA), but
the number in the high-dose EPO group was significantly preserved compared with the vehicle
and low-dose EPO groups (P < 0.0001: one-way ANOVA). This tendency was similar to that
of the number of motor neurons in H-E-stained sections (Fig 5B and 5C).
Cell counting of ChAT-positive cells. The number of ChAT-positive cells in 1 slice of
each group was 18.0 ± 1.6 (Vehicle group) and 27.7 ± 1.2 (High-dose EPO group). ChAT-posi-
tive cells in the high-dose EPO group were significantly preserved compared with the vehicle
group (P< 0.005: one-way ANOVA) (Fig 5A and 5D).
H-E staining in C2, Th4 and Th12 levels. At 16 weeks after surgery, H-E staining was
also performed at C2, Th4 and Th12 levels in the sham, vehicle and high-dose EPO groups
(Fig 6A, 6B and 6C). In C2 levels, the numbers of motor neurons were 161.6 ± 12.4 (sham
group), 141.6 ± 12.0 (vehicle group) and 141.0 ± 10.2 (high-dose EPO group). There was no
significant difference in the number of motor neurons in all groups (Fig 6D). In Th4 levels, the
numbers of motor neurons were 113.0 ± 13.4 (Sham group), 87.0 ± 3.7 (Vehicle group) and
112.3 ± 10.9 (High-dose EPO group). There was no significant difference in the number of
motor neurons in all groups although the number of motor neurons tended to be slightly
lower in vehicle group (sham vs vehicle: P = 0.1, high-dose EPO vs vehicle: 0.11, one-way
ANOVA) (Fig 6E). In Th12 levels, the numbers of motor neurons were 183.7 ± 25.5 (sham
group), 172.3 ± 0.5 (vehicle group) and 180.0 ± 10.0 (high-dose EPO group). There was no sig-
nificant difference in the number of motor neurons in all groups (Fig 6F).
TUNEL staining. TUNEL-positive cells were significantly increased in the vehicle group
compared with the other two groups (sham and high-dose EPO groups) (P < 0.0001: one-way
ANOVA) (Fig 7A and 7B). We found no significant difference between the sham and high-
dose EPO groups. The ratios of TUNEL-positive cells to DAPI-positive cells (%) were
1.72 ± 0.59% (sham group), 35.01 ± 9.17% (vehicle group), and 5.66 ± 2.27% (high-dose EPO
group). The ratio in the vehicle group was significantly higher than that in the other two
groups (P< 0.0001: one-way ANOVA), and we found no significant difference between the
sham and high-dose EPO groups (Fig 7A and 7C).
Caspase3 staining. Caspase-3 staining was performed at 10 weeks after surgery. Although
caspase-3-positive cells were detected in the vehicle group (12 ± 2.1 cells), we failed to observe
any of these cells in the high-dose EPO group (P< 0.001, unpaired t-test) (Fig 8A and 8C).
EPO-R staining. EPO-R staining was performed at 10 weeks after surgery. In all groups,
EPO-R was mainly expressed in anterior horn cells. The number of EPO-R-positive anterior
horn cells was significantly lower in the high-dose EPO group than in the vehicle group (vehi-
cle: 26.6 ± 0.9 versus EPO: 15.3 ± 2.1 cells, P< 0.005, unpaired t-test) (Fig 8A and 8B).
APP staining. There was no significant difference in the number of APP positive cells in
gray matter between the vehicle and the high dose EPO group at 10 weeks after surgery
were significantly decreased in the compression groups compared with the sham group (�P< 0.0001: one-way ANOVA). However, in the high-dose EPO group, the
number was significantly preserved compared with the other two compression groups (�P< 0.0001: one-way ANOVA). The tendency in the cell count was similar to
that with H-E staining. D: Counting of anterior horn cells in ChAT-stained tissue. ChAT-positive cells were significantly preserved in the high-dose EPO groups
compared with the vehicle group (��P< 0.005: one-way ANOVA).
https://doi.org/10.1371/journal.pone.0214351.g005
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(26.7 ± 0.5 versus 30.0 ± 2.4) (Fig 8A and 8D). However, in white matter, the number of APP-
positive cells was significantly higher in the vehicle group than in the high-dose EPO group
(53.7 ± 9.8 versus 24.3 ± 6.3; P < 0.05, unpaired t-test) (Fig 8A and 8E).
At 16 weeks after surgery, there was no significant difference in the number of APP-positive
cells in the gray matter between the vehicle and high-dose EPO group (23.7 ± 1.3 versus
21.3 ± 1.3) (Fig 9A and 9B). However, APP staining intensity in anterior horn cells was attenu-
ated in the EPO group (Fig 8A). In the white matter, there was no significant difference in the
number of APP-positive cells between the vehicle and high-dose EPO group (86.3 ± 3.3 versus
88.0 ± 7.9) (Fig 9A and 9D).
Synaptophysin staining. The number of synaptophysin-positive axons at 10 weeks after
surgery was significantly higher in the high-dose EPO group than in the vehicle group
(45.7 ± 1.7 versus 33.0 ± 1.6; P < 0.005, unpaired t-test) (Fig 8A and 8F).
The number of synaptophysin-positive axons at 16 weeks after surgery was also significantly
preserved and found to be higher in the high-dose EPO group than in the vehicle group
(27.3 ± 2.1 versus 14.7 ± 1.2; P < 0.005, unpaired t-test) (Fig 9A and 9D).
5-HT staining. Although the expression was unclear in both groups at 16 weeks after sur-
gery (Fig 9A), clear expression was detected along the nerve fibers in the gray matter of the
EPO group at 10 weeks after surgery (Fig 8A). The expression was weak in the vehicle group.
GAP-43 staining. Although GAP-43 staining was performed at 10 weeks after surgery,
the expression in the anterior horn cells was not clear in both groups (Fig 8A).
GFAP staining. GFAP staining was performed 16 weeks after surgery. The results showed
some astrocytes in the gray matter of both groups, but there was no significant difference
between the two groups (Fig 9A).
APC staining. APC staining was performed 16 weeks after surgery. Oligodendrocytes in
gray matter was 82.0 ± 2.9 cells in the vehicle group and 80.3 ± 3.9 cells in the high-dose EPO
group, and there was no significant difference between the two groups (P = 0.74: unpaired t-
test) (Fig 9A and 9E).
Hematological data
After administration of EPO, the RBC, Hb, and Ht values increased immediately in the EPO-
administered groups (low-dose and high-dose EPO groups) (P < 0.0001: two-way ANOVA).
The trend in RBC and Hb values showed a similar increasing tendency after EPO administra-
tion (Fig 10A and 10B). Eventually, the RBC and Hb values increased to approximately 1.2 and
1.4 times in the low-dose and high-dose EPO groups, respectively, compared to the baseline
value (vehicle group). The values were significantly higher in both EPO-administered groups
than the vehicle group until 6 weeks after administration (P< 0.0001: two-way ANOVA) (Fig
10A and 10B).
Fig 6. Treatment experiment: Anterior motor neurons (whole spine other than C5 levels). A: Top panels: The spinal cord at the C2 levels was sliced into 5-μm
thick sections at 16 weeks after surgery. Hematoxylin and eosin staining of cross sections of spinal cord is shown (original magnification ×4, scale bar = 100 μm).
In the compression groups, the spinal cord was flattened. Black box shows the region of the anterior horn. Second panels: The black box in the second panel was
magnified (×10, scale bar 20 μm). B: Top panels: The spinal cord at the Th4 levels was sliced into 5-μm thick sections at 16 weeks after surgery. Hematoxylin and
eosin staining of cross sections of spinal cord is shown (original magnification ×4, scale bar = 100 μm). In the compression groups, the spinal cord was flattened.
Black box shows the region of the both anterior horn. Second panels: The black box in the second panel was magnified (×10, scale bar 20 μm). C: Top panels: The
spinal cord at the CTh12 levels was sliced into 5-μm thick sections at 16 weeks after surgery. Hematoxylin and eosin staining of cross sections of spinal cord is
shown (original magnification ×4, scale bar = 100 μm). In the compression groups, the spinal cord was flattened. Black box shows the region of the anterior horn.
Second panels: The black box in the second panel was magnified (×10, scale bar 20 μm). D: Counting of anterior horn cells in H-E-stained tissue at C2 levels.
There was no significant difference in the number of motor neurons in each group (N.S: one-way ANOVA). E: Counting of anterior horn cells in H-E-stained
tissue in Th4 levels. There was no significant difference in the number of motor neurons in each group although it tended to be slightly lower in the vehicle group
(sham vs vehicle: P = 0.1, high-dose EPO vs vehicle: 0.11, sham vs high-dose EPO: 0.97, one-way ANOVA) F: Counting of anterior horn cells in H-E-stained
tissue in Th12 levels. There was no significant difference in the number of motor neurons in each group (N.S: one-way ANOVA).
https://doi.org/10.1371/journal.pone.0214351.g006
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Fig 7. Treatment experiment: TUNEL staining. A: TUNEL staining was performed to detect apoptotic cells at 10 weeks after surgery. DAPI/TUNEL double staining is
shown in each group (DAPI staining, TUNEL staining, DAPI/TUNEL staining, Bar = 100 μm). The vehicle group showed the highest number of TUNEL-positive cells.
B: The number of TUNEL-positive cells was counted in each group. The number of TUNEL-positive cells in the vehicle group was significantly higher than in the other
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The Ht value in the EPO-administered groups was the highest at 4 weeks and increased to
approximately 1.3 and 1.4 times in the low-dose and high-dose EPO groups, respectively, com-
pared to the baseline value (P< 0.0001: two-way ANOVA). At 6 weeks after administration of
EPO, the Ht value of the EPO-administered groups started to peak. The Ht value of the high-
dose EPO group was significantly higher than that of the other two groups (P = 0.005: two-way
ANOVA) at 6 weeks (Fig 10C).
rhEPO levels in spinal cord tissue
The rhEPO levels in the spinal cord 12 hours after subcutaneous injection of rhEPO was less
than 0.10 mIU/g in the vehicle group, 1.07 ± 0.46 mIU/g in the low-dose EPO group, and
8.67 ± 2.33 mIU/g in the high-dose EPO group. The rhEPO levels was remarkably higher in
the high-dose EPO group than in the other two groups (P< 0.0001: one-way ANOVA). In the
low-dose EPO group, the rhEPO levels was slightly increased, but that of the low-dose EPO
group did not show a significant difference compared with the vehicle group (Fig 11A).
The tissue % ID was 4.4 ± 1.2 (10−4%) in the high-dose EPO group and 5.4 ± 2.3 (10−4%) in
the low-dose EPO group. We found no significant difference between the two groups (Fig
11B). This result shows that the rhEPO levels in the spinal cord was dose dependent.
Discussion
The present study demonstrated that EPO improved locomotor functions and preserved
motor neurons and axons, even in developing myelopathy due to spinal cord compression.
Furthermore, EPO was transferred into spinal cord tissue following subcutaneous EPO
administration.
Some studies reported that EPO improves motor function in an experimental acute SCI
model [21, 22, 33, 34]. EPO and the EPO receptor (EPO-R) are highly expressed in both the
central and peripheral nervous systems [35]. The roles of EPO in these areas are in neuropro-
tection, angiogenesis, anti-apoptosis, and anti-inflammation [18, 24, 36]. Clinically, a prelimi-
nary randomized comparative trial was performed in patients with acute SCI. In this trial, the
effect of EPO treatment was compared with high-dose methylprednisolone treatment. EPO
had higher efficacy and fewer side effects than methylprednisolone, indicating a potential ther-
apeutic effect for acute SCI patients [25].
On the other hand, there are few studies on neuroprotective agents for degenerative cervical
myelopathy including spinal cord compression, compared to the studies in acute SCI. Among
them, Riluzole, a sodium channel blocker, has shown efficacy in animal models of degenerative
cervical myelopathy. Riluzole reduces glutamatergic excitotoxicity and improves neurological
functional outcome [37, 38, 39].
The agent is currently approved by the US Food and Drug Administration for the treatment
of amyotrophic lateral sclerosis. However, in the multicenter randomized control trial about
the combined effect of riluzole in the surgery for degenerative cervical myelopathy, the addi-
tional effect has not been confirmed in neurological improvement [40].
Methylprednisolone has been also reported to be effective in decompression surgery for an
animal model of degenerative cervical myelopathy. The addition of the agent to decompres-
sion surgery demonstrated a reduced inflammatory response, enhanced neuronal preservation
and accelerated locomotor recovery without changes to the peripheral immune cell
two groups (�P< 0.0001: one-way ANOVA), with no significant difference between the sham and high-dose EPO groups. C: The percentage of TUNEL-positive cells in
each group. The percentage in the vehicle group was significantly higher than in the other two groups (�P< 0.0001: one-way ANOVA).
https://doi.org/10.1371/journal.pone.0214351.g007
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Fig 8. Immunostaining at 10 weeks. Top panels: The spinal cord at the C5 level was sliced into 5-μm-thick sections at 10 weeks after surgery and the gray matter
was stained for EPO-R (original magnification ×40, scale bar = 20 μm). The expression of EPO-R in the anterior horn cells was clear in the vehicle group but weak
in the EPO group. Second panels: Caspase-3 staining of spinal cord is shown. The arrows indicate caspase-3-positive nuclei, which were detected in the vehicle
group but not in the EPO group. Third panels: APP staining of the gray matter of spinal cord is shown. Staining of anterior horn cells with APP was similar in
both groups. Fourth panels: APP staining in the white matter of spinal cord is shown. Arrows show APP-positive cells. More APP-positive cells were observed in
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populations [41]. However, there are very few clinical studies on the role of corticosteroids in
degenerative cervical myelopathy.
We have been investigating several neuroprotecitve agents for degenerative cervical mye-
lopathy using a spinal cord compression model. In these studies, we have shown that Lima-
prost alfadex and Cilostazol have a preventive effect on compression-induced cervical
myelopathy [8] [9]. Furthermore, we have confirmed that G-CSF not only has a preventive
effect but also a therapeutic effect in the progressive phase of compression myelopathy [10].
However, in healthy people, G-CSF causes marked leukocytosis, which commonly results in
fever, arthralgia, and rarely, thromboembolism and splenomegaly [11].
In contrast, EPO is used commonly and safely for renal anemia and preoperative autolo-
gous blood donation even in elderly patients or those with critical disease [13] [15].
On the other hand, the mechanism of neuroprotective effect of EPO for compression mye-
lopathy remains unknown.
We previously demonstrated that blood flow in the compressed segment is markedly
reduced, indicating the presence of local spinal cord ischemia in the chronic compression
myelopathy model [35].
Consistent with our previous studies [9, 10], this study also demonstrated that chronic spi-
nal cord compression induces apoptotic cell death. In hypoxic stress conditions, endogenous
EPO is produced in response to low oxygen partial pressure and protects neurons [42]. Impor-
tantly, cell apoptosis induced by spinal cord compression is inhibited by high-dose EPO
administration, indicating anti-apoptosis and anti-inflammatory effects of EPO [18, 24, 36].
Additionally, a rapid increase in RBC, Hb, and Ht values following EPO administration may
improve the local oxygen supply and restore motor function (Fig 10). Liem et al. reported that
blood transfusion for anemia improves cerebral oxygenation in newborn infants [43].
Although we could not directly evaluate local oxygen pressure, we speculate that improvement
in cervical myelopathy is due to anti-apoptotic effects of EPO, preservation of motor neurons
and axons, and improvement in local ischemia in the spinal cord with an increased oxygen
supply.
Zhu et al. found that the expression of EPO-R increases following ischemia in the central
nervous system, and that EPO treatment could reduce the expression of EPO-R by improving
the ischemia [44]. In the present study, EPO-R expression in the anterior horn cells increased
in the vehicle group but decreased in the EPO group. The results suggest that EPO improved
local ischemia (Fig 9A and 9B).
In the current study, both high-dose and low-dose EPO increased hematopoietic values
including RBC, Hb, and Ht. However, functional recovery was observed with high-dose EPO
treatment in particular. High-dose EPO may have passed through the blood-spinal cord bar-
rier. EPO is a high-molecular weight glycoprotein (30.4 kDa) [12]. In classic papers, the
blood–brain barrier (BBB) was considered to be impermeable to large glycosylated molecules
like EPO [45]. However, some recent studies have reported that EPO can pass through the
BBB due to a high concentration and after BBB disruption such as that which follows brain
the vehicle group. Fifth panels: Synaptophysin staining of the white matter of spinal cord is shown. Arrows indicate synaptophysin-positive axons. In the EPO
group, synaptophysin-positive axons extending from the gray matter to the white matter were clearly observed. Sixth panels: 5-HT staining of the gray matter of
spinal cord is shown. Nerve fibers were clearly stained with 5-HT (indicated by arrows) in the gray matter from EPO group but not in that from vehicle group.
Bottom panels: GAP-43 staining of gray matters of spinal cord is shown. The expression of positive cells was not clear in both the vehicle and EPO groups. B: The
number of EPO-R-positive anterior horn cells was significantly higher in the vehicle group (P < 0.005, unpaired t-test). C: Caspase-3-positive cells were detected
only in the vehicle group (P< 0.001, unpaired t-test). D: No significant difference was observed in the number of APP-positive cells in the gray matter between the
two groups (P = 0.13, unpaired t-test). E: Significantly more APP-positive cells were detected in the white matter of the vehicle group (P< 0.05, unpaired t-test). F:
The number of synaptophysin-positive axons was significantly higher in the high-dose EPO group (P< 0.005, unpaired t-test).
https://doi.org/10.1371/journal.pone.0214351.g008
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Fig 9. Immunostaining at 16 weeks. A Top panels: The spinal cord at the C5 levels was sliced into 5- μm thick sections at 16 weeks after surgery. APP staining
of gray matter of spinal cord is shown (original magnification ×40, scale bar = 20 μm). Arrows show APP-positive cells. The staining intensity of APP in the
anterior horn cells was lower in the vehicle group than that in the EPO group. Second panels: APP staining of the white matter of spinal cord is shown. Arrows
show APP-positive cells. Third panels: Synaptophysin staining of the white matter of spinal cord is shown. The arrows indicate synaptophysin-positive axons.
Synaptophysin-positive axons extending from the gray matter to the white matter were clearly observed in the EPO group. Fourth panels: 5-HT staining of gray
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and spinal cord contusion [46–48]. EPO can cross the BBB at 450 IU/kg or more in rats [46]
and crosses the BBB in a dose-dependent manner in a rat brain contusion model [49]. In the
current study, in fact, high-dose EPO was predominantly transferred into the spinal cord tissue
12 hours after EPO subcutaneous administration, probably resulting from passing through the
blood-spinal cord barrier. Transfer of EPO into spinal cord tissue was dose dependent (Fig
11A), and the transfer activity was almost the same between the low-dose and high-dose EPO
groups (Fig 11B). This finding demonstrates that the higher the dose of EPO that was adminis-
tered, the more EPO can transfer into spinal cord tissue. This result indicates that EPO directly
matter of spinal cord is shown. The expression of 5-HT was not clear in both groups. Fifth panels: Astrocytes were occasionally observed in the gray matter of
both groups. The arrows indicate astrocytes. Bottom panels: Oligodendrocytes were occasionally observed in the gray matter of both groups. The arrows indicate
oligodendrocytes. B: There was no significant difference in the number of APP-positive cells in the gray matter between the two groups (P = 0.13, unpaired t-
test). C: There was no significant difference in the number of APP-positive cells in the white matter between the two groups (P = 0.80, unpaired t-test). D: The
number of synaptophysin-positive axons was significantly higher in the high-dose EPO group (P< 0.005, unpaired t-test). E: There was no significant difference
in the number of APC-positive oligodendrocytes between the two groups (P = 0.74: unpaired t-test).
https://doi.org/10.1371/journal.pone.0214351.g009
Fig 10. Treatment experiment: Hematological data. A: Time course of red blood cells (RBCs). RBCs increased immediately
in the low-dose and high-dose EPO groups (P < 0.0001: two-way ANOVA). From 4 weeks after administration, we found a
significant difference between the low-dose and high-dose EPO groups (P< 0.0001: two-way ANOVA). Eventually, RBCs
increased up to approximately 1.2 and 1.4 times in the low-dose and high-dose EPO groups, respectively, compared with the
vehicle group. B: Time course of hemoglobin (Hb). The Hb value increased immediately in the low-dose and high-dose EPO
groups (P< 0.0001: two-way ANOVA). The time course was similar to that of RBCs. Eventually, the Hb value increased up to
approximately 1.2 and 1.4 times in the low-dose and high-dose EPO groups, respectively, compared with the vehicle group. C:
Time course of hematocrit (Ht). The Ht value increased immediately in the low-dose and high-dose EPO groups (P< 0.0001:
two-way ANOVA). The Ht value was the highest at 4 weeks, and then peaked. The maximum Ht value was approximately 1.3
and 1.4 times in the low-dose and high-dose EPO groups, respectively, compared with the vehicle group.
https://doi.org/10.1371/journal.pone.0214351.g010
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affected the spinal cord to provide neuronal protection and indirectly affected the cord by
increasing RBC, Hb, and Ht values.
Dhillon et al. examined the changes in the expression of APP (marker of axonal injury),
serotonin (axonal neurotransmitter), synaptophysin (synaptic markers), and GAP-43 (axonal
growth marker) in a model of spinal cord compression [32]. They showed the increase in the
expression of APP and the decrease in the expression of serotonergic neurons and synaptophy-
sin upon spinal cord compression. On the other hand, surgical decompression of the spinal
cord reduced the expression of APP, recovered serotonergic fibers and synaptophysin expres-
sion, and increased the expression of GAP-43[32]. In other words, surgical decompression led
to the recovery and plasticity of axons. In the present study, we found that the expression of
APP reduced in the white matter of the EPO group at 10 weeks after surgery (Fig 8A and 8E).
The staining intensity of APP-positive cells decreased in the gray matter at 16 weeks after sur-
gery (Fig 9A), suggestive of the partial inhibition of axonal injury. Although the expression of
GAP-43 was not obvious (Fig 8A), 5-HT was abundantly expressed in the EPO group at 10
weeks after surgery (Fig 8A). Axons with synaptophysin expression were significantly pre-
served in the EPO group compared to the vehicle group at 10 and 16 weeks after surgery (Fig
8A, 8F and Fig 9A and 9D).
Considering the above changes in APP, 5-HT, and synaptophysin, EPO administration
may improve motor function through the protection and plasticity of axons, including seroto-
nergic axons. Zhao et al. [50] also reported the axonal protection effect of EPO, consistent with
our findings.
Here, we also observed the changes of astrocytes and oligodendrocytes and found no signif-
icant difference between groups treated with or without EPO (Fig 9A and 9E).
To summarize the above findings, EPO administration for spinal cord compression can
improve motor function through the inhibition of apoptosis of the anterior horn cells, preser-
vation of motor neurons, and protection and plasticity of axons.
Fig 11. Treatment experiment: ELISA of recombinant human EPO (rhEPO). A: The amount of rhEPO per 1 g spinal cord tissue. The rhEPO levels was significantly
higher in the high-dose EPO group compared to the other two groups (�P< 0.0001: one-way ANOVA). B: The tissue rhEPO levels for injected dose (%ID) in the low-
dose and high-dose EPO groups. No significant difference was found in the %ID between the two groups.
https://doi.org/10.1371/journal.pone.0214351.g011
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The dosage of EPO (500 IU/kg or 5000 IU/kg) in this study was decided based on previous
reports in acute or subacute SCI with no side effects including hematological complications
[21, 51–53].
EPO has been used in clinical practice for a long time, and knowledge of the hematopoietic
effect, clinical safety, and side effects of EPO has accumulated. The possible side effects of EPO
in humans include hypertension, coagulation disorders, and polycythemia [54]. However, no
adverse effects occurred in brain injury patients treated with 10000 IU/kg for 7 consecutive
days [55]. In a recent preliminary randomized comparative trial (EPO versus methylpredniso-
lone) for human acute SCI, EPO (500 IU/kg) had a predominant effect and no adverse effects
compared with high-dose methylprednisolone. Based on these data, EPO may be a clinically
acceptable agent for progressive compressive myelopathy as well as a hematopoietic cytokine.
Polycythemia vera (erythemia) is defined as a Hb value more than 18.5 in males and 16.5 in
females by WHO guidelines [56]. In practical clinical use, EPO should be used while monitor-
ing of RBC, Hb, and Ht values, especially in hematologically healthy people. Administration of
EPO is indicated for patients with anemia and those waiting for surgery and expecting preop-
erative hematopoietic effects.
The effect of EPO treatment gradually declined at 4 weeks after EPO administration in this
rat model of cervical myelopathy, although the group given high-dose EPO was finally superior
to the group given NS in terms of motor functions. Therefore, the best treatment period may
be limited to several weeks after EPO administration, and surgical decompression may be con-
sidered during that period.
Certainly, continuous administration of EPO to patients with simple degenerative cervical
myelopathy over a long period seems unrealistic considering the side effects and high costs.
Practical clinical use of EPO may occur for a limited period, especially in patients with worsen-
ing symptoms of degenerative cervical myelopathy who have higher systemic risks such as
severe anemia, older age, and diabetes mellitus, and those who live far from a hospital that per-
forms spinal surgery. Furthermore, EPO may be effective against surgical complications such
as compression myelopathy due to postoperative epidural hematoma and spinal alignment
failure. EPO itself can be effective against degenerative cervical myelopathy, but may be more
synergistic when combined with decompression surgery.
The detailed mechanisms of the neuroprotective effect of EPO for degenerative cervical
myelopathy still remain to be elucidated. In addition, in this study, the changes in local blood
flow and oxygen partial pressure in the spinal cord were not elucidated.
However, this study suggests that EPO may inhibit anterior horn cell apoptosis, preserve
motor neurons, induce protection and plasticity of axons, and improve motor function. This
study strongly suggests that EPO has potential for treating patients with degenerative cervical
myelopathy, and may be worth reconsidering for clinical use to provide both neuroprotective
and hematopoietic effects. Further investigations including larger randomized controlled trials
with long-term follow-up surveys are required to establish the clinical efficacy of EPO treat-
ment and elucidate therapy-related adverse events.
Conclusions
EPO improved motor function in rats with spinal cord compression-induced cervical myelop-
athy. EPO suppressed neuronal cell apoptosis, protected motor neurons, and induced axonal
protection and plasticity. The neuroprotective effects were produced following transfer of EPO
into the spinal cord tissue. These findings suggest that EPO has high potential as a treatment
for degenerative cervical myelopathy.
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